<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 5:46<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If4991bd16b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="Id8e3eb20933b11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>5.</label.designator><headtext>Factors in Deciding Whether Transfer Is Appropriate</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f30039e1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>5:46.</label.designator><headtext>Arguments rejected by the Panel—Differences in progress of actions</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>The Panel has not taken a uniform approach to this factor. <eos/><bos/>It has specifically mentioned it as a basis for denying transfer where one of two actions was approaching trial while the other had only recently been filed.[<eos/><bos/><footnote.reference refid="If4991bd26b3e11e99b03e53d6dd36aa2">1</footnote.reference>] This conclusion can be explained in part, however, by the fact that only two actions were involved, a fact frequently cited by the Panel in denying transfer.[<eos/><bos/><footnote.reference refid="If49942e06b3e11e99b03e53d6dd36aa2">2</footnote.reference>] The Panel has declined to order transfer of a single advanced action for coordinated or consolidated pretrial proceedings with a group of relatively unadvanced actions for which transfer is ordered.[<eos/><bos/><footnote.reference refid="If49942e26b3e11e99b03e53d6dd36aa2">3</footnote.reference>] Where only two actions are involved, no transfer can be ordered. <eos/><bos/>Minor differences in advancement of the cases would not be significant to the Panel.<eos/></paratext><eop/></para><para><bop/><bos/><paratext>The Panel has also declined to deny transfer of some cases merely because they are closer to trial than others being transferred.[<eos/><bos/><footnote.reference refid="If49969f06b3e11e99b03e53d6dd36aa2">4</footnote.reference>] The Panel has noted that the transferee court can consider that issue, and remand those cases that are ready to be tried. <eos/><bos/>The Panel has also noted that the transferee court can formulate a program for management of the cases to accommodate the differing needs of the various cases.[<eos/><bos/><footnote.reference refid="If49969f16b3e11e99b03e53d6dd36aa2">5</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>The Panel is prone to reject arguments that differences in the progress of actions should prevent transfer, pointing out that the transferee judge can suggest remand whenever particular actions are ready for remand.[<eos/><bos/><footnote.reference refid="If49969f26b3e11e99b03e53d6dd36aa2">6</footnote.reference>] If the argument is made that the actions are different in their management needs, the Panel will point out that the transferee judge is free to manage them differently.[<eos/><bos/><footnote.reference refid="If49969f36b3e11e99b03e53d6dd36aa2">7</footnote.reference>] The Panel is similarly not unduly persuaded that the benefits of centralization on cases that have not progressed as well would come at the expense holding back those cases that have progressed further toward resolution.[<eos/><bos/><footnote.reference refid="If49969f46b3e11e99b03e53d6dd36aa2">8</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>Where the differences in the progress are significant, the Panel may give some weight to the differences and decline to transfer.[<eos/><bos/><footnote.reference refid="If49969f56b3e11e99b03e53d6dd36aa2">9</footnote.reference>]</paratext><eos/><eop/></para></section.body></section><author.footnotes><footnote ID="If4991bd16b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If4991bd26b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914048" w-serial-number="1976126388" w-seq-number="00001" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="388" ID="I82b316b16b3e11e99f73e2698c313519">In re McDonnell Douglas “Wild Weasel AN/APR-38” Contract Litigation, 415 F. Supp. 387, 388 (J.P.M.L. 1976)</cite.query>. <eos/><bos/><ital>See also</ital> <cite.query w-src-number="0304914048" w-serial-number="2011788242" w-seq-number="00002" w-ref-type="RP" w-pub-number="0004637" ID="I82b316b36b3e11e99f73e2698c313519">In re Katz Interactive Call Processing Patent Litigation, 481 F. Supp. 2d 1353 (J.P.M.L. 2007)</cite.query> (Panel rejects argument that cases are in different stages of development); <ital>but see</ital> <cite.query w-src-number="0304914048" w-serial-number="2034977561" w-seq-number="00003" w-ref-type="RP" w-pub-number="0007903" ID="I82b316b56b3e11e99f73e2698c313519">In re: Cymbalta (Duloxetine) Products Liability Litigation, 65 F. Supp. 3d 1393 (U.S.J.P.M.L. 2014)</cite.query> (wide variety in progress of actions cited as reason for denying centralization).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49942e06b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext>The role played by number of actions is discussed in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs5:18" w-pub-number="185218" ID="If49942e16b3e11e99b03e53d6dd36aa2">§ 5:18</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49942e26b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext>Partial transfer is discussed in § § 5:57 to 5:59. <eos/><bos/>The Panel&apos;s treatment of tag-along actions where the cases differ in their advancement toward trial is discussed in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs8:4" w-pub-number="185218" ID="If49942e36b3e11e99b03e53d6dd36aa2">§ 8:4</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49969f06b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914048" w-serial-number="2016316634" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I82b49d516b3e11e99f73e2698c313519">In re Cessna 208 Series Aircraft Products Liability Litigation, 560 F. Supp. 2d 1380 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914048" w-serial-number="2002269017" w-seq-number="00005" w-ref-type="RP" w-pub-number="0004637" ID="I82b49d536b3e11e99f73e2698c313519">In re Mirtazapine Patent Litigation, 199 F. Supp. 2d 1380 (J.P.M.L. 2002)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49969f16b3e11e99b03e53d6dd36aa2"><label.designator>5</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914048" w-serial-number="1987070350" w-seq-number="00006" w-ref-type="RP" w-pub-number="0000345" ID="I82b539916b3e11e99f73e2698c313519">In re Rail Collision Near Chase, Md. on Jan. 4, 1987, 661 F. Supp. 69 (J.P.M.L. 1987)</cite.query>; <cite.query w-src-number="0304914048" w-serial-number="1986162810" w-seq-number="00007" w-ref-type="RP" w-pub-number="0000345" ID="I82b539936b3e11e99f73e2698c313519">In re Dow Chemical Co. Sarabond Products Liability Litigation, 650 F. Supp. 187 (J.P.M.L. 1986)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49969f26b3e11e99b03e53d6dd36aa2"><label.designator>6</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914048" w-serial-number="2022312165" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I82b5fce16b3e11e99f73e2698c313519">In re Zimmer Durom Hip Cup Products Liability Litigation, 717 F. Supp. 2d 1376 (J.P.M.L. 2010)</cite.query>; <cite.query w-src-number="0304914048" w-serial-number="2019952801" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I82b5fce36b3e11e99f73e2698c313519">In re Yasmin, Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation, 655 F. Supp. 2d 1343 (J.P.M.L. 2009)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49969f36b3e11e99b03e53d6dd36aa2"><label.designator>7</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914048" w-serial-number="2022312165" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I82b672116b3e11e99f73e2698c313519">In re Zimmer Durom Hip Cup Products Liability Litigation, 717 F. Supp. 2d 1376 (J.P.M.L. 2010)</cite.query> citing Cyclobenzarine HCL; <cite.query w-src-number="0304914048" w-serial-number="2020075922" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I82b672136b3e11e99f73e2698c313519">In re Stanford Entities Securities Litigation, 655 F. Supp. 2d 1360 (J.P.M.L. 2009)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49969f46b3e11e99b03e53d6dd36aa2"><label.designator>8</label.designator><footnote.body><para><bop/><bos/><paratext>See, e.g., <cite.query w-src-number="0304914048" w-serial-number="2020646618" w-seq-number="00012" w-ref-type="RP" w-pub-number="0004637" ID="I82b70e516b3e11e99f73e2698c313519">In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, 657 F. Supp. 2d 1375 (J.P.M.L. 2009)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49969f56b3e11e99b03e53d6dd36aa2"><label.designator>9</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914048" w-serial-number="2037398546" w-seq-number="00013" w-ref-type="RP" w-pub-number="0007903" ID="I82b783816b3e11e99f73e2698c313519">In re Pilepro Antitrust and Patent Litigation, 140 F. Supp. 3d 1350 (J.P.M.L. 2015)</cite.query> (vastly different procedural postures); <cite.query w-src-number="0304914048" w-serial-number="2037398381" w-seq-number="00014" w-ref-type="RP" w-pub-number="0007903" ID="I82b783836b3e11e99f73e2698c313519">In re Domestic Airline Travel Antitrust Litigation, 140 F. Supp. 3d 1344 (J.P.M.L. 2015)</cite.query> (rejecting motion to join an existing docket where cases far more advanced).<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 5:46<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
